Stem Cell Therapy is not one standard treatment. Different therapies use different cell types, sources and preparation methods, and they may be intended for completely different medical conditions. Understanding these differences matters when comparing treatments or deciding whether a regenerative orthopaedic approach could be appropriate for you.
Blood-Forming vs Mesenchymal Stem Cells
One of the biggest differences is the type of stem cell being used.
Haematopoietic stem cells are blood-forming cells found in blood and bone marrow. Stem cell and bone marrow transplants use these cells to replace damaged blood-forming cells in people with certain blood cancers, blood disorders and immune-system conditions. The NHS describes these as established hospital treatments that may use either a patient's own cells or cells from a suitable donor.
These treatments are very different from the Stem Cell Therapy commonly discussed for joint or cartilage problems.
Orthopaedic research has focused largely on mesenchymal stromal or stem cells. These cells can be obtained from sources including bone marrow, adipose tissue and, in some research settings, umbilical cord tissue or other sources.
Clinical studies of knee osteoarthritis have investigated bone marrow-derived, adipose-derived and peripheral blood-derived cell treatments. However, differences in the source and preparation of the cells mean that findings from one treatment cannot automatically be applied to another.
Where Do the Cells Come From?
Another important difference is whether the cells come from the patient or from somebody else.
Autologous treatment uses cells obtained from your own body. In orthopaedics, this may involve cells or cell-containing preparations obtained from bone marrow or adipose tissue.
For example, the Royal National Orthopaedic Hospital describes a procedure for selected patients with focal knee cartilage damage in which bone marrow is harvested from the patient's pelvis, concentrated and then used during cartilage repair surgery. The hospital also makes clear that this type of treatment is not considered effective for established osteoarthritis.
Allogeneic treatment, by comparison, uses cells from a donor. Some clinical research into osteoarthritis has assessed donor-derived cells, including umbilical cord-derived mesenchymal cells.
Neither approach can automatically be described as better. A systematic review of knee osteoarthritis studies found that outcomes differed according to cell source, while the available evidence was not sufficient to show that every source produces the same clinical result.
This is why the phrase Stem Cell Therapy alone tells you relatively little about the actual treatment being offered.
Does the Way Cells Are Prepared Matter?
Yes. Two treatments using cells from the same tissue can still be very different.
Some procedures use preparations produced relatively soon after bone marrow or adipose tissue has been collected. Others may involve isolating and expanding particular cell populations in a laboratory before they are administered.
Research into knee osteoarthritis demonstrates just how varied these approaches can be. Published clinical trials differ in their donors, cell sources, preparation methods, doses and delivery techniques.
Bone marrow aspirate concentrate, for example, should not automatically be treated as identical to a purified or laboratory-expanded mesenchymal stem cell product. Concentrated bone marrow contains a mixture of different cell types and biological components.
How extensively cells are processed can also affect how a treatment is regulated.
In the UK, certain cell-based medicinal products may meet the definition of an Advanced Therapy Medicinal Product. The MHRA regulates ATMPs, which include somatic cell therapies and tissue-engineered medicinal products.
Patients should therefore ask exactly what preparation is being offered rather than assuming all treatments marketed under the same general label are equivalent.
Which Type Is Best for Joint Problems?
There is currently no single form of orthopaedic Stem Cell Therapy that can be described as universally best for every joint condition.
Research into knee osteoarthritis has reported potential improvements in pain with both bone marrow- and adipose-derived stromal cell treatments. However, studies have not consistently demonstrated that symptom improvement translates into substantial restoration of joint function or reliable cartilage regeneration.
The condition being treated matters just as much as the cell source. A focal cartilage injury in a younger patient is different from widespread osteoarthritis, and evidence relating to the knee cannot automatically be applied to the hip, shoulder or another joint.
A specialist assessment should therefore establish your diagnosis, the extent of joint damage, previous treatments and your goals before discussing whether any regenerative treatment is appropriate.
Understand Which Treatment You Are Being Offered
The term Stem Cell Therapy can describe treatments that differ substantially in their cell type, source, preparation and intended purpose. Blood-forming stem cell transplantation is an established treatment for certain serious diseases, while many musculoskeletal cell therapies remain developing areas of regenerative medicine.
If you are considering regenerative treatment for joint pain, ask where the cells come from, how they are prepared, what evidence supports their use for your condition and what results can realistically be expected.
Contact Regenesis to arrange a specialist assessment and discuss whether Stem Cell Therapy or another regenerative orthopaedic treatment may be appropriate for your individual condition.
Comments